Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > David Sinclair Joins Lux Capital as Venture Partner

Abstract:
Harvard Medical School Associate Professor and Serial Entrepreneur Brings Added Life Sciences Expertise to Leading Venture Capital Firm

David Sinclair Joins Lux Capital as Venture Partner

New York, NY | Posted on December 20th, 2007

WIRE)--Lux Capital Management, a leading venture capital firm, today announced that David Sinclair, Ph.D. has joined the firm as a Venture Partner.

Dr. Sinclair is a co-founder of both Sirtris Pharmaceuticals (NASDAQ: SIRT) and Genocea Biosciences, and is Associate Professor of Pathology at Harvard Medical School and Director of the Glenn Laboratories for the Biological Mechanisms of Aging. He has made key contributions to the scientific understanding of aging, making him one of the most highly published and respected scientists in biology. In 1997, Dr. Sinclair identified the cause of aging in yeast, a first for any species, and in 2003 reported the discovery of a conserved master regulatory gene controlling this process. His laboratory at Harvard is currently focused on slowing diseases of aging in mammals using genetic and pharmacological means. In 2004, Dr, Sinclair co-founded Sirtris Pharmaceuticals and helped grow it into one of the most successful biotech companies in recent years.

Dr. Sinclair has authored over 50 peer-reviewed scientific publications, including several seminal papers in Nature, Cell and Science. His work has been reported in most of the leading news media including the Wall Street Journal, New York Times, TIME and Newsweek. He has received numerous awards and honors for his research. Dr. Sinclair performed his post-doctoral work with Dr. Leonard Guarente at M.I.T. and holds a Ph.D. in Biochemistry and Molecular Genetics from the University of New South Wales, Australia. Dr. Sinclair was honored by Genzyme with the Outstanding Achievement in Biomedical Science Award for 2004. Dr. Sinclair will remain an Associate Professor at Harvard Medical School and is currently a Director at Sirtris Pharmaceuticals.

"David is not only one of the most published scientists in the field of biology, but also an experienced serial entrepreneur," said Robert Paull, Managing General Partner at Lux Capital. "His addition to the Lux Capital team strengthens our life sciences investment initiatives and expands our presence in the Northeast."

"Lux Capital is second to none when it comes to rapidly building value," said Dr. Sinclair. "Their ability to assist entrepreneurs in hiring world leading operators and scientific experts, finding non-dilutive sources of capital, and opening doors to corporate partners is unparalleled. I look forward to working with Lux to find and build value around the most exciting new technologies in the life sciences."

"David is one of the most promising rising entrepreneurs in life sciences," said Lux Capital Special Limited Partner Larry Bock. "We're excited to have him on the Lux team." Bock joined Lux in 2004 and has co-founded or provided seed financing to 40 companies that have achieved a cumulative market capitalization of over $40 billion. Bock has won the Einstein Award for lifetime contributions in the field of life sciences and was named one of Venture Capital Journal's Ten Most Influential Venture Capitalists.

Lux Capital's team has been responsible for co-founding more than 20 startups, including some of the world's leading biotechnology companies such as Vertex Pharmaceuticals (NASDAQ: VRTX), Illumina Inc. (NASDAQ: ILMN), Caliper Technologies (NASDAQ: CALP), Neurocrine Biosciences (NASDAQ: NBIX) and Ariad Pharmaceuticals (NASDAQ: ARIA). Recent life sciences investments include Genocea Biosciences (vaccine discovery), Tempo Pharmaceuticals (nanoparticle drug delivery) and Magen Biosciences (aesthetic medicine/dermatology).

####

About Lux Capital Management
Lux Capital Management is a research-driven investment firm focused on de novo, seed and early stage investments in the physical and life sciences. Lux takes an active role in helping management teams build successful businesses in high growth sectors. Our investment team has built over 20 companies from scratch.

For more information, please click here

Contacts:
Lux Capital Management
Bibi Masara, 646-723-2217

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Transparent Conductive Films and Sensors Are Hot Segments in Printed Electronics: Start-ups in these fields show above-average momentum, while companies working on emissive displays such as OLED are fading, Lux Research says April 17th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

'Life Redesigned: The Emergence of Synthetic Biology' Lecture at Brookhaven Lab on Wednesday, April 30: Biomedical Engineer James Collins to Speak for BSA Distinguished Lecture Series April 16th, 2014

ECHA Planning Workshop on Regulatory Challenges in the Risk Assessment of Nanomaterials April 16th, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Announcements

Transparent Conductive Films and Sensors Are Hot Segments in Printed Electronics: Start-ups in these fields show above-average momentum, while companies working on emissive displays such as OLED are fading, Lux Research says April 17th, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014

Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMC’s Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE